Uppsala 3 June, 2019


Promising results with PharmaShell® coated protein

Nanexa has conducted trials where an active protein is coated with PharmaShell® coating. In the experiments performed at Nanexa’s development laboratory in Uppsala, we see that we obtain a slow and controlled release of the protein, as was expected from our drug delivery system. We have also shown that the PharmaShell® coated protein retains its biological activity after it has gone through the manufacturing process, which is crucial for developing long-acting protein-based drugs.

Many new drugs are based on proteins that have a specific treatment activity for a particular disease. In many cases, it is crucial to maintain that activity for a long time in order to obtain the best effect of the protein. We have now shown that it can be made possible with the help of a PharmaShell® based depot preparation that releases new protein for a long time. The new results strengthen our position and add further information, showing that PharmaShell® can be a very competitive tool for creating such drugs.


Nanexa’s CEO David Westberg comments:

The need for good drug delivery technologies to create long-acting peptide and protein drugs is great. In addition to the results mentioned above, PharmaShell® enables the creation of a drug with high drug load. My assessment is that these results will be very interesting for companies that develop protein-based drugs.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.